Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab for Severe COVID-19 (Phase II, Randomized, Open-Label)
2021-002098-25Phase 2Completed
- Sponsor
- Friedrich Schiller University Jena
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) and airway morbidity comparing Infliximab (Remsima) + standard of care with Standard of care (2 arms). Primary endpoint: 28-day mortality. Started May 2021; status: completed.
02
Drugs
infliximab
03
Conditions
coronavirus disease 2019 (COVID-19)airway morbidity
Beyond the preview
Go deeper on 2021-002098-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002098-25.